Treatment of Hepatitis B Related Acute-On-Chronic Liver Failure with Nucleotide/Nucleoside Analogues

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the clinical efficacy of three nucleotide/nucleoside analogues—Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide—in treating patients with hepatitis B virus-related acute-on-chronic liver failure (ACLF). Given the high mortality rate associated with ACLF in China, the study aims to provide valuable data on the effectiveness of these antiviral treatments, particularly focusing on Tenofovir Alafenamide, which has limited data in this context. Participants will be monitored for their response to the treatments over a specified period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Positive hepatitis b surface antigen or hepatitis b virus DNA \> 0.5 year;
2. Age from 12 to 65 years old;
3. Serum total bilirubin level \> 10 times upper limit of normal;
4. Prothrombin time activity \< 40% or prothrombin time international ratio \> 1.5；
5. Do not receive nucleotide/nucleoside analogues treatment in the past half year.

Exclusion Criteria:

1. Other active liver diseases;
2. Hepatocellular carcinoma or other malignancy;
3. Pregnancy or lactation;
4. Human immunodeficiency virus infection or congenital immune deficiency diseases;
5. Severe diabetes, autoimmune diseases;
6. Other important organ dysfunctions;
7. Using glucocorticoid;
8. Patients can not follow-up;
9. Investigator considering inappropriate.

Where it's running

• Third Affiliated Hospital of Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Liang Peng, Doctor — Third Affiliated Hospital, Sun Yat-Sen University
• Study coordinator: Wenxiong Xu, Doctor
• Email: xwx1983@163.com
• Phone: +8613760783281

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term outcomes for patients recovering from hepatitis B related liver failure

  This study looks at the long-term health and recovery of people who have survived liver failure caused by hepatitis B to see how they are doing over time.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT04310787

• Entecavir 0.5 mg vs 1.0 mg daily in adults with HBV-related decompensated cirrhosis

  This trial tests whether 0.5 mg or 1.0 mg of entecavir once daily can better lower HBV DNA in adults with HBV-related decompensated cirrhosis over 24 weeks.

  Recruiting Phase 4 Bangladesh Medical University · Dhaka, Dhaka Division · NCT07816094

• Hepatitis B in Zambia: an observational cohort of adults with HBV, with or without HIV

  This observational cohort follows adults diagnosed with hepatitis B in Zambia, with and without HIV coinfection, to see how their liver disease and HBV (and HIV when present) change over several years while they receive standard care.

  Recruiting at 3 sites University of Alabama at Birmingham · Lusaka and 2 other locations · NCT07589985

• Factors that affect how well mesenchymal stromal cell (MSC) therapy works for hepatitis B–related acute-on-chronic liver failure.

  This project will look back at people with hepatitis B–related ACLF who received MSC infusions to see which factors affect whether the treatment helps.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07198854

• Long-term outcomes of pegylated interferon alfa-2b in families with clustered hepatitis B and high risk of cirrhosis or liver cancer

  This study will try pegylated interferon alfa-2b to see if it improves long-term outcomes for people with chronic hepatitis B from families where cirrhosis or liver cancer affects two generations.

  Recruiting First Affiliated Hospital Xi'an Jiaotong University · Xi'an, Shaanxi and 1 other locations · NCT07079150

• Comparing two treatments to prevent hepatitis B transmission from mothers to infants

  This study is testing whether two different antiviral treatments can help prevent pregnant women with high hepatitis B levels from passing the virus to their babies.

  Recruiting Guangzhou 8th People's Hospital · Guangzhou, Guangdong and 9 other locations · NCT06947356

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.